Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the “Company”, an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is ...
VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-1 1 with a maximal effect observed at 0.5mg to 1.0 mg QD. For more information on the Phase 1a trial results, please ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...